1. Annual report 2024
  2. Research
  3. ISAC

ISAC

Interventions in Health and Community Activities

Multidisciplinary cross-disciplinary group made up of 20 professionals of different profiles who carry out their research in Primary Care (6 doctors and 5 doctoral students), frequently collaborating with other groups and entities.

Her lines of research are related to lifestyle interventions, preventive health promotion activities (nutrition, smoking, physical activity, vaccines), and quality and patient safety, with a focus on communities, using information and communication technologies (ICTs).

Different members of the group have led projects funded in competitive calls (FIS, PERIS, IDIAPJGol, etc.) and have obtained funding from contracts and agreements with European entities.

The group takes into account the gender perspective, citizen participation, dissemination and socialization of science. As for scientific dissemination, priority will be given to the publication "OpenAcces" and in the SCIENTIA digital repository of the Department of Health.

Group projects

  • INTENSIFICATION 2024: ISCIII intensification grants for: Effectiveness of an online training in cardiopulmonary resuscitation maneuvers to a network of volunteers to increase survival in cardiopulmonary arrest. EFORCP study.
  • Health interventions and community activities: line of research on smoking. (INTENS-23/3). ICS - Catalan Institute of Health. 2024-2026. IP: Antoni Santigosa Ayala.
  • Effect of the Mediterranean Diet on lung function in smokers without previous respiratory pathology: the MEDIS-TAR (Mediterranean Diet and Smoking in Tarragona) clinical trial. Batesttini Prize 2023 COL· college of physicians of Tarragona. 2023-2026. PI: Francisco Martín Luján.
  • Grup TICS-AP: Tecnologies de la informació i Comunicació en Atenció Primària. INTENS -23 ICS - Institut Català de la Salut. 2023. IP: Ester Granado Font.
  • Usefulness and performance of the detection of spirometric alterations through a mobile application in asymptomatic smokers. ICS - Institut Català de la Salut. 2022-2026. PI: Darinka Savic Pesic.
  • ISAC. (2021 SGR 00884). Agència de Gestió d'Ajuts Univ i de Recerca. 2022-2025. PI: Francisco Martín Luján.
  • IMPACT Platform - Program 1 Predictive Medicine IMP/00021. (IMP/00021). Consortium Center for Biomedical Research in RED (CIBER); Carlos III Health Institute. 2020-2024. PI: Josep Basora Gallisà.
  • Alliance on Health Innovation and Industrialisation of the Mediterranean axis. (PT20/00147). Carlos III Health Institute. 2020-2024. PI: Josep Basora Gallisà.
  • Effectiveness of a motivational intervention based on spirometry results to achieve smoking cessation in primary healthcare patients: randomised, parallel, controlled multicentre study. Premi Batesttini 2022 COL· LEGI OFICIAL DE METGES DE TARRAGONA. PI: Francisco Martín Luján.
  • ICS 2022 Expert Research Tradition Award. ICS - Institut Català de la Salut. PI: Cristina Rey Reñones.
  • Effectiveness of an App for smoking cessation in pregnant women (TOBBGEST). Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). PI: Maria Agràs Guàrdia. App for smoking cessation therapy. TOBBSTOP. PI: Cristina Rey Reñones.
  • Integration of the primary care pharmacist/pharmacologist into the primary care team. PI: Ferran Bejarano Romero.
  • ATDOM risk map. Jordi Gol i Gurina Primary Care Research Institute (IDIAPJGol). PI: Nuria Hernández Vidal.
  • Evaluation of the efficacy of 2 Audit & Feedback interventions to reduce the potentially inappropriate prescription of medication and the prescription of antibiotics in primary care. AIMab Study: Multicenter Clinical Trial. (PI22/01669). Carlos III Health Institute. 2024-2026. IP: Ferran Bejarano Romero.
  • Effectiveness of an online training in cardiopulmonary resuscitation maneuvers to a network of volunteers to increase survival in cardiopulmonary arrest. EFORCP study. (PI23/00288). Carlos III Health Institute. 2024-2026. IP: Ester Granado Font.
  • Effectiveness of an educational intervention on hand hygiene in students of sentinel schools. 2023-2026. PI: Josep Basora Gallisà.
  • Evaluation of SINERGIAPS-2, an intervention aimed at improving patient safety in health centers in Spain based on the perceptions and experiences of the patients themselves. 2023-2026. PI: Montserrat Gens Barberà.
  • Eficàcia d'una formació online en maniobres de Ressuscitació cardiopulmonar i l'ús del Desfibril·lador Extern Automatitzat (DEA) a través d'una plataforma virtual. 2023-2026. IP: Cristina Rey Reñones.
  • Consum i experiència amb el tabac durant l'embaràs. Estudi qualitatiu. 2023-2026. IP: Cristina Rey Reñones.
  • VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe. Research Triangle Institute (RTI). 2023-2026. IP: Felipe Villalobos Martínez.
  • Clinical course, outcomes and risk factors of myocarditis following administration of mRNA-1273 (ELASOMERAN). Julius Clinical Research B.V. 2023-2025. IP: Felipe Villalobos Martínez.
  • Self-controlled case series (SCCS) study of COVID-19 vaccines and myocarditis and pericarditis (GVDN-VAC4EU-Myocarditis). 2022-2025. IP: Felipe Villalobos Martínez.
  • VITTLINK: A multi-centre international database study evaluating the association of vaccine-induced thrombosis and thrombocytopenia (VITT) with COVID-19 vaccination. 2022-2024. IP: Felipe Villalobos Martínez.
  • Risk of Guillain-Barré syndrome (GBS) after COVID-19 vaccination and SARS-CoV-2 infection: A self-controlled risk interval study. 2022-2024. IP: Felipe Villalobos Martínez.
  • Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen. UMC Utrecht (University Medical Center Utrecht). 2022-2024. IP: Felipe Villalobos Martínez.
  • Salud pública y Medicina preventiva de precisión combinando exploración física, hábitos de vida e información genómica: monitorización de la pandemia de obesidad a través de extensión de la Cohorte IMPaCT (Obes-IMPaCT). (PMP/00003). Instituto de Salud Carlos III. 2022-2025. IP: Josep Basora Gallisà.
  • Proyecto INSIGNIA. Una iniciativa para mejorar el seguimiento de los pacientes con Enfermedad Pulmonar Obstructiva Crónica. AstraZeneca Farmacéutica Spain, S.A. 2022-2025. IP: Francisco Martín Luján.
  • Disseny i avaluació d'una plataforma interactiva d'activitats comunitàries promogudes des de l'atenció primària per a fomentar la salut i el benestar en una població d'una àrea bàsica de salut. (SLT021/21/000073). Generalitat Catalunya. 2022-2025. IP: Maria Roser Pedret Llaberia.
  • Evaluation of patient safety in primary care in Spain based on the perceptions and experiences of the patients themselves: SINERGIAPS 2 study. (PI22/01822). Carlos III Health Institute. 2022-2025. PI: Montserrat Gens Barberà.
  • Effectiveness of a mobile app in smoking cessation in pregnant women (TOBBGEST): a randomized community trial. (PI21/01058). Carlos III Health Institute. 2021-2026. PI: Cristina Rey Reñones.
  • Impact of a rapid diagnostic test that allows discriminating the viral origin of the bacterium in acute respiratory infections (ARI) of the upper tract in pediatric age. 2021-2024. PI: Josep Basora Gallisà.
  • An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU. Teamit Institute, S.L. 2021-2025. PI: Felipe Villalobos Martínez.
  • Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries. Julius Clinical Research B.V. 2021-2024. PI: Felipe Villalobos Martínez.
  • Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (WP1). European Medicines Agency (EMA). 2021-2024. PI: Felipe Villalobos Martínez.
  • Evaluation of the level of biomarkers of effect and exposure to air pollution in blood and urine samples of residents depending on the distance to the petrochemical complex (PETROMARKER). 2021-2024. PI: Francisco Martín Luján.
  • Authorization Active Surveillance Safety Study using secondary data to monitor real-world safety of Spikevax in Europe. ICS - Institut Català de la Salut; Julius Clinical Research B.V. 2021-2025. IP: Felipe Villalobos Martínez.
  • Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (WP3). Vaccine Monitoring Collaboration for Europe (VAC4EU). 2021-2024. IP: Felipe Villalobos Martínez.
  • Post-Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID -19) Vaccine. (C4591021). Fondazione Penta ETS. 2021-2025. IP: Felipe Villalobos Martínez.
  • Projecte validació de mascaretes FFP2-CSIC. Gomà-Camps, S.A.U. 2021-2024. IP: Josep Basora Gallisa
  • Drug Utilization Study (DUS). Estudi transversal, multi-països amb múltiples fonts de dades sobre la utilització de medicaments utilitzant bases de dades electròniques. [Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases. IQVIA Information, S. A. 2017-2024. IP: Josep Basora Gallisà.
  • Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe. (C4591052). 2024-2027. IP: Felipe Villalobos Martínez.
  • A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU: Study protocol for the occurrence of flares of Graves´ disease, Hashimoto´s thyroiditis, polyarteritis nodosa, autoimmune hepatitis, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, erythema nodosum, systemic lupus erythematosus, and ulcerative colitis using electronic healthcare data sources. European Medicines Agency (EMA). 2024-2027. IP: Felipe Villalobos Martínez.
  • A framework for the post-authorisation safety monitoring and evaluation of vaccines in the EU. Universiteit Utrecht. 2024-2027. IP: Felipe Villalobos Martínez.
  • Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID 19) Vaccine. (C4591038). Fondazione Penta ETS. 2022-2025. IP: Felipe Villalobos Martínez.
  • Non-interventional post-authorization study (EPAS) for active safety surveillance of recipients of the Pfizer-BioNTech mRNA COVID-19 vaccine in the EU. Pfizer, S.A. 2021-2024. PI: Felipe Villalobos Martínez.

Grou Publications

  • Ahmadizar F, Fortuny J, Royo AC, Plana E, Weinrib R, Esteban RG et al. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment. Pharmacoepidemiol Drug Saf. 2024;33506-507.
  • Agràs Guàrdia M, Martínez Torres S, Satué E, Granado Font E, Pallejà Millán M, Patricio D et al. Experiences of smoking and tobacco use during pregnancy: A qualitative study protocol. PLoS One. 2024; 19(8):PMID:39121101.
  • Bellitto C, Luxi N, Ciccimarra F, L'Abbate L, Raethke M, van Hunsel F et al. What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study. Drug Saf. 2024; 47(10):1011-1023. PMID:38907947.
  • Bots SH, Belitser S, Groenwold RHH, Durán CE, Riera Arnau J, Schultze A et al. Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design -evaluating COVID-19 vaccine safety signals, using myocarditis as a case example. Am. J. Epidemiol. 2024; 194(1):208-219. PMID:38960670.
  • Cabré JJ, Barrio F, Vizcaíno J, Martínez A, Mur T, Sagarra R et al. Results of the implementation of the DP-TRANSFERS project in Catalonia: a translational method to improve diabetes screening and prevention in primary care. Rev Clin Esp (Barc). 2024; 224(9):569-579. PMID:39216807.
  • Canadell Vilarrasa L, Palanques Pastor T, Campabadal Prats C, Salom Garrigues C, Conde Giner S, Bejarano Romero F. Impacto de una unidad de farmacia de atención primaria en la optimización del tratamiento farmacológico de pacientes diabéticos tipo 2. Aten Primaria. 2024; 56(9):102945-102945. PMID:38663157.
  • Cendra Duarte E, Canals J, Iglesias Vázquez L, Jardí C, Martín Luján F, Arija V. Adherence to the Mediterranean diet during pregnancy and behavioural problems at 4 years of age. Matern. Child Nutr. 2024; 20(4):PMID:38990125.
  • Cendra Duarte E, Canals J, Becerra Tomás N, Jardí C, Martín Luján F, Arija V. Maternal dietary patterns and offspring behavioral problems. Pediatr Res. 2024; PMID:39266631.
  • Ciccimarra F, Luxi N, Bellitto C, L'Abbate L, Raethke M, van Hunsel F et al. Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study. Vaccines (Basel). 2024; 12(3):PMID:38543875.
  • Clua Espuny JL, Gentille Lorente D, Hernández Pinilla A, Satué Gracia EM, Pallejà Millán M, Martín Luján FM et al. MVP Risk score and new atrial fibrillation diagnosis: Prospective cohort PREFATE study. Aten Primaria. 2025; 57(1):103071-103071. PMID:39265318.
  • Cruz A, Cuxart Graell A, Goncalves AQ, Vazquez Villegas J, Vallejo Godoy S, Salas Coronas J et al. Delivering an innovative multi-infection and female genital mutilation screening to high-risk migrant populations (ISMiHealth): study protocol of a cluster randomised controlled trial with embedded process evaluation. BMJ Open. 2024; 14(11):PMID:39496367.
  • Ahmadizar F, Fortuny J, Royo AC, Plana E, Weinrib R, Esteban RG et al. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment. Pharmacoepidemiol Drug Saf. 2024;33506-507.
  • Agràs Guàrdia M, Martínez Torres S, Satué E, Granado Font E, Pallejà Millán M, Patricio D et al. Experiences of smoking and tobacco use during pregnancy: A qualitative study protocol. PLoS One. 2024; 19(8):PMID:39121101.
  • Bellitto C, Luxi N, Ciccimarra F, L'Abbate L, Raethke M, van Hunsel F et al. What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study. Drug Saf. 2024; 47(10):1011-1023. PMID:38907947.
  • Bots SH, Belitser S, Groenwold RHH, Durán CE, Riera Arnau J, Schultze A et al. Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example. Am. J. Epidemiol. 2024; 194(1):208-219. PMID:38960670.
  • Cabré JJ, Barrio F, Vizcaíno J, Martínez A, Mur T, Sagarra R et al. Results of the implementation of the DP-TRANSFERS project in Catalonia: a translational method to improve diabetes screening and prevention in primary care. Rev Clin Esp (Barc). 2024; 224(9):569-579. PMID:39216807.
  • Canadell Vilarrasa L, Palanques Pastor T, Campabadal Prats C, Salom Garrigues C, Conde Giner S, Bejarano Romero F. Impacto de una unidad de farmacia de atención primaria en la optimización del tratamiento farmacológico de pacientes diabéticos tipo 2. Aten Primaria. 2024; 56(9):102945-102945. PMID:38663157.
  • Cendra Duarte E, Canals J, Iglesias Vázquez L, Jardí C, Martín Luján F, Arija V. Adherence to the Mediterranean diet during pregnancy and behavioural problems at 4 years of age. Matern. Child Nutr. 2024; 20(4):PMID:38990125. .
  • Cendra Duarte E, Canals J, Becerra Tomás N, Jardí C, Martín Luján F, Arija V. Maternal dietary patterns and offspring behavioral problems. Pediatr Res. 2024; PMID:39266631.
  • Ciccimarra F, Luxi N, Bellitto C, L'Abbate L, Raethke M, van Hunsel F et al. Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study. Vaccines (Basel). 2024; 12(3):PMID:38543875.
  • Clua Espuny JL, Gentille Lorente D, Hernández Pinilla A, Satué Gracia EM, Pallejà Millán M, Martín Luján FM et al. MVP Risk score and new atrial fibrillation diagnosis: Prospective cohort PREFATE study. Aten Primaria. 2025; 57(1):103071-103071. PMID:39265318.
  • Cruz A, Cuxart Graell A, Goncalves AQ, Vazquez Villegas J, Vallejo Godoy S, Salas Coronas J et al. Delivering an innovative multi-infection and female genital mutilation screening to high-risk migrant populations (ISMiHealth): study protocol of a cluster randomised controlled trial with embedded process evaluation. BMJ Open. 2024; 14(11):PMID:39496367.
  • Durán CE, Riefolo F, Gini R, Barbieri E, Messina D, Garcia P et al. Incidence of severe and non-severe SARS-CoV-2 infections in children and adolescents: a population-based cohort study using six healthcare databases from Italy, Spain, and Norway. Eur J Pediatr. 2024; 184(1):6-6. PMID:39535547.
  • Esteban Cledera L, Bissacco CA, Pallejá Millán M, Villalobos M, Villalobos F. Association between COVID-19 Vaccines and Menstrual Disorders: Retrospective Cohort Study of Women Aged 12-55 Years Old in Catalonia, Spain. Int J Environ Res Public Health. 2024;21(8):PMID:39200699.
  • Fiol-deRoque MA, Mansilla GV, Maderuelo-Fernández JA, Tamayo-Morales O, Martín-Luján F, Astier-Peña P, Chacón-Docampo M, Orrego C, Gens-Barberà M, Andreu-Rodrigo P, Ricci-Cabello I; SinergiAPS team. Evaluation of SINERGIAPS, an intervention to improve patient safety in primary healthcare centers in Spain based on patients' perceptions and experiences: a protocol for a hybrid type I randomized clinical trial. Front Public Health. 2024 Mar 26;12:1324940. doi: 10.3389/fpubh.2024.1324940. PMID: 38596515; PMCID: PMC11003190.
  • Fiol deRoque MA, Valderas JM, de la Torre JA, Serrano Ripoll MJ, Gens Barbera M, Sánchez Freire E et al. Evaluation of the psychometric performance of the Spanish and Catalan versions of the patient reported experiences and Outcomes of Safety in Primary Care (PREOS-PC)-Compact questionnaire. Eur J Gen Pract. 2024; 30(1):2296573-2296573. PMID:38197321.
  • Garcia Vilana S, Kumar V, Kumar S, Barberia E, Landin I, Granado Font E et al. Study of risk factors for injuries due to cardiopulmonary resuscitation with special focus on the role of the heart: A machine learning analysis of a prospective registry with multiple sources of information (ReCaPTa Study). Resusc Plus. 2024;17100559-100559. PMID:38586866.
  • Gens Barberà M, Astier Peña MP, Hernández Vidal N, Hospital Guardiola I, Bejarano Romero F, Oya Girona EM et al. Patient Safety Incidents in Primary Care: Comparing APEAS-2007 (Spanish Patient Safety Adverse Events Study in Primary Care) with Data from a Health Area in Catalonia (Spain) in 2019. Healthcare (Basel). 2024;12(11):PMID:38891161.
  • Girardi A, Limoncella G, Hyeraci G, Roberto G, Bartolini CC, Paoletti O et al. Impact of Data Source Diversity on the Distribution of Key Variables in Pregnancy Cohorts Based on the ConcePTION Pregnancy Algorithm Leveraging a Random Forest Imputation Model. Pharmacoepidemiol Drug Saf. 2024;3379-80.
  • Hernández Pinilla A, Clua Espuny JL, Satué Gracia EM, Pallejà Millán M, Martín Luján FM, PREFA TE S. Protocol for a multicentre and prospective follow-up cohort study of early detection of atrial fibrillation, silent stroke and cognitive impairment in high-risk primary care patients: the PREFA-TE study. BMJ Open. 2024;14(2):PMID:38373864.
  • Jiménez NG, Satué Gracia E, Contel JC, Gallisà JB, Amblàs Novellas J. Feasibility, Reliability, and Validity of the VIG-Express Questionnaire as an Instrument for Rapid Multidimensional Geriatric Assessment: A Multicenter Study. Aten Primaria. 2025;57(4):PMID:39454430.
  • Luque V, Feliu A, Closa Monasterolo R, Muñoz Hernando J, Ferré N, Gutiérrez Marín D et al. Impact of the motivational interviewing for childhood obesity treatment: The Obemat2.0 randomized clinical trial. Pediatr Obes. 2024; 19(7):PMID:38733242.
  • Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T et al. Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study. Vaccines (Basel). 2024; 12(9):PMID:39340089.
  • Maisonneuve E, Ciccimarra F, Luxi N, Bellitto C, Raethke M, Van Hunsel F et al. Cohort Event Monitoring of COVID-19 Vaccine Safety Using Patient-Reported Outcomes in Pregnant Women. Pharmacoepidemiol Drug Saf. 2024;33451-452.
  • Maisonneuve E, Ciccimarra F, Luxi N, Bellitto C, Raethke M, van Hunsel F et al. Cohort Event Monitoring of COVID-19 Vaccine Safety Using Patient-Reported Outcomes in Lactating Women. Pharmacoepidemiol Drug Saf. 2024;33187-187.
  • Mercadé Besora N, Guo Y, Du M, Li X, Ramírez Anguita JM, Moreno A et al. Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID-19 Pandemic. Arthritis Care Res (Hoboken). 2024; 76(8):1173-1178. PMID:38523562.
  • Motevalizadeh E, Díaz-López A, Martín F, Basora J, Arija V. Association of Parity With Insulin Resistance Early in Pregnant Women: ECLIPSES Study. J Clin Endocrinol Metab. 2024 Feb 20; 109(3):730-739. doi: 10.1210/clinem/dgad594. PMID: 37804535.
  • Pareja Rossell C, Rabanal Tornero M, Oliva G, Gens Barberà M, Hospital Guardiola I, Hernandez Vidal N et al. Patient safety reporting and learning system of Catalonia (SNiSP Cat): a health policy initiative to enhance culture, leadership and professional engagement. BMJ Open Qual. 2024; 13(3):1-11. PMID:39117393.
  • Raethke M, van Hunsel F, Luxi N, Lieber T, Bellitto C, Mulder E et al. Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study. Vaccine. 2024; 42(9):2357-2369. PMID:38448322.
  • Roberto G, Messina D, Durán CE, Riera Arnau J, Garcia P, Martín Pérez M et al. Assessing the Impact of Data Diversity on Background Incidence Rates of Adverse Events of Special Interest: The Component Strategy from the COVID-19 Vaccine Monitoring Project. Pharmacoepidemiol Drug Saf. 2024;33111-111.
  • Romero Aroca P, Verges R, Pascual Fontanilles J, Valls A, Franch Nadal J, Mundet X et al. Referable Diabetic Retinopathy Prediction Algorithm Applied to a Population of 120,389 Type 2 Diabetics over 11 Years Follow-Up. Diagnostics (Basel). 2024; 14(8):PMID:38667478.
  • Salom Garrigues C, Aragonès E, Giralt M, Prats CC, Bejarano Romero F, Canadell L. Evaluation of a pharmacist-led intervention to reduce drug-related problems in patients included in a home healthcare program: study protocol for a pragmatic randomized clinical trial. BMC Geriatr. 2024; 24(1):170-170. PMID:38373937.
  • Schultze A, Martin I, Messina D, Bots SH, Belitser SV, Carreras JJ et al. A Comparison of Self-Controlled Study Designs in an Analysis of COVID-19 Vaccines and Myocarditis Using Five European Databases. Pharmacoepidemiol Drug Saf. 2024;3334-34.
  • Schultze A, Martin I, Messina D, Bots S, Belitser S, José Carreras Martínez J et al. A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases. Vaccine. 2024; 42(12):3039-3048. PMID:38580517.
  • Schultze A, Martin I, Messina D, Bots S, Belitser S, Carreras Martínez JJ et al. Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048]. Vaccine. 2025;44126438-126438. PMID:39396886.
  • Taverna Llauradó E, Martínez Torres S, Granado Font E, Pallejà Millán M, Del Pozo A, Roca Biosca A et al. Online platform for cardiopulmonary resuscitation and automated external defibrillator training in a rural area: a community clinical trial protocol. BMJ Open. 2024 Feb; 14(2):e079467. doi:10.1136/bmjopen-2023-079467. Epub 2024 Feb 07. pmc:PMC10859986. PMID:38326271.
  • Weibel D, de Luise C, Royo AC, Ryan O, Vaz T, Aguado J et al. Interim Results from the VAC4EU Post-Authorization Safety Study (PASS) Among Recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) Vaccine in Europe. Pharmacoepidemiol Drug Saf. 2024;33499-499.
Anar a l'inici